

I DO want change I DO
feel hope I DO remember
him I DO honor her
I DO believe in clinical
t r i a l s

I DO

I DO see progress I DO spread
the word I DO join the
fight I DO it for my
fellow warriors I DO give

• • •

I DO support PHASE ONE

Tia's Hope Supports Phase One
in memory of Tia Palermo

HOPE HAPPENS

THROUGH PHASE ONE



Tia's Hope

You can't spell "Hope Happens" without Phase One

*In memory of
Bernard and Wendy Goldhirsh
the Goldhirsh-Yellin Foundation
congratulates
Phase One
on their groundbreaking work
in cancer research.*

PHASE ONE

Congratulations on many years
of great work!

Diane and Roger Duhl

We are proud to support
Phase One



Kayne Foundation
Suzanne & Ric Kayne
Jenni Kayne-Ehrlich & Richard Ehrlich

*In loving memory of
Tia Palermo Ravich*



*Jody and David
Lippman*

I DO

I DO support PHASE ONE

• • •

15th Annual Gala
Thursday, April 30, 2015

Wallis Annenberg Center for the Performing Arts

• • •

**FUNDING RESEARCH FOR 15 YEARS.
LET'S COMMIT TO 15 MORE.**

EVENT COMMITTEE

• • •

CO-CHAIRS

Meritt Elliott

Stacy Valner

Edyn Elliott Barber

Holly Baril

Emily Bernstein

Leslie Birnbaum

Marina Cohn

Leanna Creel

Emily Current

Natalie Fair

Jill Roberts Freeman

Alyson Fine Marmur

Marci Foster

Maryann Gold

Angela Kay

Kaye Popofsky Kramer

Brooke Lande

Dana Levine

Janet Lonner

Zoe Ravich McNitt

Linda Meadow

Mieke Neumann

Elissa Phillips

Missy Polson

Kimberly Reed

Stephanie Sandler

Tema Schrage

Debra Silverstein

Anna Suddleson

Suzette Swalwell

Alyssa Weinberger

• • •

EVENT COORDINATORS

FTA Events and Marketing

INVITATION DESIGN

Edyn Elliott Barber

JOURNAL DESIGN

Lissa Mozur Zanville

WE DO support PHASE ONE

A MESSAGE FROM THE GALA CO-CHAIRS

Dear Friends,

Our theme this year, I DO support PHASE ONE, is a vow recommitting to the fight against cancer. We honor the past 15 years we have funded research and commit to funding 15 more!

As you all know, Phase One was founded in 1999 after Alberto had successfully completed his treatment for testicular cancer. Sadly, Kevin was not as fortunate and lost his battle to brain cancer in 2009. This year, together, we join forces and fight on in Kevin's memory to fight cancer.

Indeed, because of the generous support of friends like you, we are doing great things. Incredible progress is being made in finding safer and more effective treatments.

We thank our wonderful event committee for all their hard work. We thank the board for their support and trust in following our vision for this evening. We thank the wonderful team of doctors who dream to find a cure.

This year, our virtual journal has allowed us to donate even more money to treatment and research. Thank you for your support and understanding that "going virtual" allows for more dollars funding research as we save on printing a paper journal.

Together we can make a difference in the fight against cancer and we thank you for your support and for saying "**I DID support PHASE ONE**".



Meritt Elliott



Stacy Valner



WE DO support PHASE ONE

A MESSAGE FROM THE BOARD OF DIRECTORS

April 30, 2015

Dear Friends,

On behalf of the Phase One Board of Directors – Welcome to the 15th Annual Gala.

Fifteen! Many of you attending tonight have been to every single Phase One Gala beginning in 2000 at L'Ermitage Beverly Hills. For some of you, this is your first Gala, and you are in for an extraordinary evening!

One thing we all have in common is that we are here this evening to support early cancer research and clinical trials.

Since that first Gala, we have raised more than \$15 million, funded dozens of clinical trials at the best medical institutions in Southern California and grown to over 3,000 supporters. This is a legacy we can ALL be proud of.


We are thrilled that PHASE ONE co-founder **Stacy Valner** and board member **Meritt Elliott** are chairing tonight's event. Along with their superb and dedicated committee, Meritt and Stacy have done an outstanding job in creating another one-of-a-kind evening.

The theme for tonight -- I DO -- is a pledge for recommitment. A recommitment to PHASE ONE. A recommitment to those we have lost. A recommitment to those we love who are fighting cancer. A recommitment to finding a cure for cancer.

The PHASE ONE Board is proud to lead in this recommitment. We have accelerated our efforts to advance research and therapies for the treatment of cancer by deploying the funds we have raised through your generous donations. We are visiting all of the major medical facilities in Los Angeles, meeting with new investigators. This year, we are funding the exciting ovarian cancer research of **Dr. Sanaz Memarzadeh** at the UCLA Broad Stem Cell Center. Tonight, guests at the Gala are able to add their own individual support, via smartphones, to her important work.

Phase One is growing – and growing stronger. This year we welcomed **Edward Woods** to our board. Thank you for joining our quest. We are redesigning our website (www.phaseonefoundation.org) and adding wonderful new programs in support of our mission. Join our mailing list (info@phaseonefoundation.org) to learn more.

None of this would be possible without you. Thank you for all you DO to support PHASE ONE!



MARINA COHN
2015 Chair, Board of Directors

WE DO support PHASE ONE

A MESSAGE FROM THE FOUNDERS



Dear Friends,

As many of you know, a little over sixteen years ago, my mother and I were diagnosed with very different types of cancer. Unfortunately for my mother, at the age of 58 and in the epitome of health, she had a type of cancer where little was known, and she was given a year to live.

Nine days later, I was also diagnosed with cancer. Even though my cancer had pretty much spread throughout my body, a lot was known about the type of cancer I had and my odds of survival were more optimistic. After six months of intensive chemotherapy treatments and multiple surgeries, I was told I was “cancer free.” Just a few days later, my mother passed away.

Both my mother and I were treated by some of the best doctors and medical facilities that Southern California has to offer. The primary difference between our illnesses was the knowledge or lack of that existed regarding each one of our cancers.

Therefore, fifteen years ago, Stacy and I became determined to make it our mission to raise funds for all types of cancer research. Our hope was that no one should be as unfortunate as my mother was, and that every cancer patient be provided with a sense of hope. A small group of friends joined with us and Phase One was born. Today, this group of people has grown and evolved into a large and diverse one representing all walks of life in our city. I am very proud and thankful for their commitment and leadership. In the last fifteen years, we have funded millions of dollars for cancer research at every major medical center and research facility in our greater Los Angeles community as well as at various other national institutions.

Incredible progress is being made on a daily basis in finding safer and more effective treatments. We are certain that one day cancer will be controlled and ultimately cured in our lifetimes and Phase One is determined to stay in the forefront of this quest.

We thank you for sharing our vision and for your support.

All my best,

A handwritten signature in dark ink, appearing to read "Alberto Valner". The signature is stylized with a large, sweeping loop at the end.

Alberto Valner

WE DO support PHASE ONE

WHO WE ARE



BOARD OF DIRECTORS

Marina Cohn
Chairperson

Diane V. Allen
Holly Baril
Royce Bergman
Jordan R. Bernstein
Leanna Creel
Emily Current
Carly de Castro
Meritt Elliott
Mark Freeman

Cecily Jackson-Zapata
Angela Kay
Kaye Popofsky Kramer
Janet Lonner
Alyson Fine Marmur
Zoe Ravich McNitt
Bradley Meadow
Cary Meadow
Azita Mosbat

Mieke Neumann
Kelly Newman
Tia Palermo*
Missy Polson
Steven Romick
Stephanie Sandler
Alberto Valner
Edward Woods

*(1959-2012)

Lissa Mozur Zanville
Executive Director

• • •

MEDICAL ADVISORY BOARD

Robert Figlin, MD
Chairperson
Cedars-Sinai Medical Center

Stephen J. Forman, MD
City of Hope

Heinz-Josef Lenz, MD
USC/Norris Cancer Center

Philip H. Koeffler, MD
Cedars-Sinai Medical Center

Frank L. Meyskens, Jr., MD
UC Irvine Medical Center/
Chao Family Comprehensive Cancer Center

• • •

256 26th Street · Suite 201 · Santa Monica · California · 90402
310.458.7715 phone · 310.393.6051 fax · www.phaseonefoundation.org · info@phaseonefoundation.org
@PhaseOneLA
Facebook · Twitter · Instagram

WE DO support PHASE ONE

WHAT WE DO

PHASE ONE is a non-profit organization dedicated to supporting Phase I clinical research and treatment programs for patients with cancer. The group was founded in 1999 by Stacy and Alberto Valner, with a small group of friends, all couples with young children. Each one of these individuals had been affected by a diagnosis of cancer in themselves or in a close family member.

Once a new idea or novel drug is identified in the laboratory, the FDA requires three levels of clinical testing prior to the approval of that drug for widespread use. These studies are usually referred to as trials in Phase I, II, or III. The focus of a Phase I trial is to determine the appropriate dose and schedule of a given drug and its side effects. Patients enrolled usually have advanced cancers, which have progressed through standard therapy or for which standard therapy does not exist. Sometimes these patients have been through "everything" and still function extremely well. The Phase II trial applies the Phase I information on dose and schedule and tries to get a hint of efficacy. The Phase III trial is the final set of studies and usually involves hundreds, if not thousands of patients worldwide. Clinical trials are the only way to understand the best and safest therapies available to patients with any disease.

With your support PHASE ONE hopes that its efforts to fund Phase I trials and research will help in the fight against cancer, by finding treatments that will transform what might be a terminal illness into one where patients can live a full and productive life. PHASE ONE is determined to:

- Offer hope to the patient today that has been told there is nothing left.
- Allow patients in our community the access to whatever types of therapy may be available around the world.
- Make the time a patient goes through treatment easier by improving patient care.
- Support research that takes advantage of the vast amount of new information about what causes cancers.
- Lay the groundwork for larger scale multi-center research that can set new standards of oncology care.
- Make sure that those diagnosed with cancer in the future will have even safer and more effective treatments to live long lives with their disease too.

Since 1999, PHASE ONE has raised more than \$15 million in support of these trials and programs at some of the most prestigious organizations in Southern California including Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, City of Hope, UCLA Jonsson Comprehensive Cancer Center, USC/Norris Comprehensive Cancer Center, Children's Hospital of Los Angeles and the Premiere Oncology Foundation Lung Cancer Initiative.

WE DO support PHASE ONE

WHAT WE SUPPORT

Dedicated to ensuring that the Southern California community has access to the most promising novel therapies available for those afflicted with cancer, PHASE ONE directed its efforts to support research that might not be funded by alternative mechanisms.

The studies selected included novel therapies and conventional ones, all having some scientific question about efficacy, biologic correlates, surrogate markers (radiographic, laboratory, tissue based or other), or mechanism of action. The findings of these studies will ideally lead to further research or further independently-funded projects.

2015

Dr. Sanaz Memarzadeh, UCLA Broad Stem Cell Research Center

Grant Amount: \$300,000

PHASE ONE is funding a two-year grant, totaling \$300,000, in support of Sanaz Memarzadeh's, MD, PhD, ovarian cancer research at the UCLA Broad Stem Cell Research Center.

Research suggests that most, if not all, cancers arise from cancer stem cells. Conventional cancer therapies target rapidly dividing tumor cells, but cancer stem cells have tools to escape chemotherapy and radiation. At some point, the cancer stem cells begin to self-renew, creating a new tumor and the cancer begins to grow again.

Ovarian tumors account for about 3% of all malignancies in women, but are responsible for a disproportionately large number of cancer related deaths. One reason these cancers are dangerous is that they are detected late. The symptoms of ovarian cancer are often non-specific and can resemble other common ailments. Currently, there is no definitive screening test for ovarian cancer; therefore tumors cannot be detected at an early stage.

High grade serous tumors are the most common form of ovarian cancer. Despite being called "ovarian" cancer, recent work suggests that the majority of these tumors have their origins in the fallopian tubes. The standard of treatment for high grade serous ovarian cancer is surgical removal of the tumor followed by chemotherapy. However, most patients with high grade serous ovarian cancer relapse in one year and many succumb to this illness within five years despite a complete initial response to therapy. The clinical behavior of high grade serous ovarian cancer suggests that subsets of these tumor cells have stem cell-like properties and are resistant to existing therapies. These cells comprise a small fraction of the tumor but are the cancer initiating cells. In order to eradicate serous cancers, we must first find a way to target the serous cancer stem cells.

UCLA Broad Stem Cell Research Center member Dr. Sanaz Memarzadeh and her team have made major progress in isolating this population of serous tumor cells with stem activity (the cancer stem cells). They believe these cells are responsible for high rates of relapse in ovarian cancers. More importantly, they have identified and are testing ways of eliminating these tumor cells by adding drugs to existing standard chemotherapy. They envision a handful of strategies that can be used to individualize each patient's care based on tumor analysis in the laboratory. Their proposed treatments may significantly improve survival of patients. With the generous support from the PHASE ONE Foundation, Sanaz is moving the first of these therapeutic strategies forward into clinical trial for treatment of ovarian cancer.

As a practicing clinician it is Sanaz's experience caring for patients with ovarian and other gynecological cancers that motivate her to define better, less toxic and more effective treatments to replace or compliment conventional therapies. Historically, ovarian cancer research is woefully underfunded; generous philanthropic resources enhance Sanaz's ability to pursue innovative and novel ideas that will greatly impact future treatments of this disease.

2014

Dr. Richard Tuli, Cedars-Sinai Medical Center

Grant Amount: \$323,423

Pancreatic adenocarcinoma is a devastating disease with the lowest survival rate of any solid cancer. Gemcitabine chemotherapy and radiotherapy given concurrently remain the mainstay treatments for patients with locally advanced pancreatic cancer, which cannot be removed by surgery, but also has not spread to other areas of the body. Both gemcitabine and radiotherapy kill tumor cells by interfering with their DNA, the genetic blueprint. Veliparib is a poly (ADP-ribose) polymerase (PARP)1/2 inhibitor; PARP1/2 proteins are also involved in DNA repair. Studies have shown that inhibiting PARP1/2 activity can significantly enhance the effects of radiotherapy and chemotherapy in killing tumor cells. Our own laboratory work has shown excellent synergy between veliparib (a PARP inhibitor), radiotherapy and gemcitabine in killing pancreatic cancer cells grown in culture, and in prolonging survival in mice with pancreatic tumors.

Based upon these promising results and with the generous support of the PHASE ONE Foundation and Diane V. Allen, we are currently enrolling patients in a first-in-human, investigational clinical study (phase I) to test the safety and efficacy of veliparib in combination with gemcitabine and radiotherapy in patients with locally advanced pancreatic cancer. Prior to and during therapy, patient tumor and blood samples will also be tested for levels of different DNA repair proteins and mutations, such as BRCA1/2. This molecular "signature" will hopefully serve as a "biomarker" to predict how the patient and tumor are responding to treatment. We are hopeful that we will be able to select out the subset of favorable patients who respond to this regimen, and design future studies (phase 2/3) by "personalizing" treatments using PARP1/2 inhibitors.

2013

Dr. Karim Chamie, University of California Los Angeles

Grant Amount: \$142,350

Dr. Karim Chamie, with UCLA Urology, is working to combat the rapid increase in recent years of urothelial cancer by investigating a potentially new treatment method involving a hydrogel polymer (chemical compound), which is liquid at room temperature, mixed with chemotherapy to treat this difficult-to-detect and highly reoccurring form of cancer. The polymer-chemotherapy combination takes on the shape of the cavity of interest (such as a kidney) at body temperature and has the potential to deliver chemotherapy to the targeted site while minimizing side-effects. The polymer can also be mixed with a dye that binds to tumor cells to facilitate detection of tumor cells within a specific organ. Traditionally, what has been most challenging in treating this type of cancer is the ability to deliver the chemotherapeutic agent at a high concentration level to the exact tumor site. This new discovery has the potential to overcome the previous challenge by using the polymer-chemotherapy directly to the targeted site. Dr. Chamie and his team are optimistic in pursuing this study and are grateful to the PHASE ONE Foundation for supporting these efforts.

Dr. Joseph Riss, University of California Los Angeles

Grant Amount: \$310,000

Despite advancement in targeted treatments, metastatic kidney cancer poses a therapeutic challenge due to its resistance to conventional models of treatment. As long-term survival for patients with metastatic kidney cancer remains poor, UCLA Urology's Allan Pantuck, MD and Arie Belldegrun, MD, along with Joseph Riss, PhD, have been working for years to develop innovative methods of therapy. With the assistance of critical funding provided by the PHASE ONE Foundation, this research team developed a kidney cancer vaccine that was recently approved by the FDA and given to the first patient in February 2013. Even with this grand milestone, the researchers must now monitor the effectiveness of the vaccine, especially given the kidney tumor's resistance to current therapeutics. With the continuous support of the PHASE ONE Foundation, Dr. Riss and his team will use previously identified indicators to develop diagnostic tools for monitoring the new treatment and aim to develop a next-generation vaccine that will combat tumor resistance in metastatic kidney cancer.

Dr. Anna Pawlowska, City of Hope

Grant Amount: \$37,000

Ewing's sarcoma is the second most common primary bone tumor in children and adolescents. While advances in treatment have increased survival rates for children with localized disease to nearly 70 percent, fewer than 30 percent of patients who experience relapse or the spread of their cancer survive. In addition to these grim statistics, there is no nationally accepted "gold standard" of treatment for patients with advanced Ewing's sarcoma. More effective therapies are urgently needed to save the lives of young patients.

City of Hope will be launching a five-year pilot clinical trial to study the effectiveness of a promising treatment for high-risk patients with advanced Ewing's sarcoma: whole-body MRI-guided radiation therapy followed by autologous hematopoietic cell transplant, with a novel combination of high-dose chemotherapy. Led by Anna Pawlowska, M.D., Clinical Professor of Pediatrics, the proposed study will assess whether this therapy is feasible, safe and likely to increase patient survival rates. A similar approach tested in Germany and Austria increased children's survival rate to 70 percent after two years and 56 percent after three years with minimal toxicity, but this approach has never been tested in the United States.

In a novel approach, guests at the 2013 PHASE ONE Gala DIRECTLY donated \$37,000 to help fund part of this five-year trial by supporting MRI tests for patients not covered by their insurance and/or support a portion of the salary of a Clinical Research Assistant. This critical seed funding would help young patients with Ewing's sarcoma access a promising new therapy **now** and start collecting the patient data needed to secure additional public and private funding for future years of the trial.

2012

Dr. Antoni Ribas, University of California Los Angeles

Grant Amount: \$294,400

With the support of the PHASE ONE Foundation we will conduct a phase 1 clinical trial (MART-1 F5 TCR Engineered Adoptive Cell Transfer Therapy with CTLA4 Blockade) with the goal of genetically programming the human immune system to efficiently target cancer cells in patients with advanced stage melanoma, the deadliest of skin cancers. This clinical trial builds upon the experience at UCLA over the past 3 years in the use of T cell receptor (TCR) engineered adoptive cell transfer therapy. This therapy is manufactured in-house and results in the generation of a large army of immune system cells that are genetically redirected to recognize and kill melanoma. With this therapy we have noted high initial response rates, but tumors come back. A major limitation has been a progressive decrease in the antitumor functionality of the TCR engineered immune cells. The antibody tremelimumab blocks a major negative regulator in immune cells and will be tested with the goal of maintaining the cancer killing functionality of the TCR engineered lymphocytes given to patients. This protocol has administrative approval by the UCLA regulatory committees and it has already been filed and approved by the Food and Drug Administration.

2011

P.R. Lowenstein, M.D. PhD and Maria G. Castro, PhD

Department of Neurosurgery and Cell and Developmental Biology, The University of Michigan School of Medicine, Ann Arbor, Michigan

Grant Amount \$216,000

Highly malignant brain tumors are uniformly lethal. Patients usually survive less than 2 years post-diagnosis, with very few still alive 5 years later. In spite of constant developments in surgery, radiotherapy and chemotherapy a breakthrough for this particularly aggressive cancer has not been yet discovered. Over the last ten years we have developed a novel approach for the treatment of brain tumors. Based on an evolutionary and developmental understanding of the structure and function of the brain immune system, we decided to reconstitute to the brain those immune cells normally absent from it, as a potential new approach to treat brain tumors. The immune cells normally absent from the brain are those in charge of turning on the anti-tumor immune response. Their absence from the brain helps us explain why normally anti-brain tumor immune responses are ineffective. By attracting those specific immune cells to the brain and the brain tumors, we expect them to identify brain tumor antigens and unleash a therapeutically effective immune attack to eliminate brain tumors. To achieve this we have turned adenoviruses which normally can cause lung infections and other diseases into therapeutic agents. We have engineered the viruses to deliver directly to the brain and the brain tumors a protein that will recruit the missing immune cells to the brain to start a clinically effective immune response. As our work uses viruses as agents of treatment to induce immune responses, our therapeutic approach is described as a “combined gene-and immune therapy”. Following more than ten years of development and experimental testing we are now ready to start clinical trials in patients suffering from glioblastoma multiforme. With very generous support from the PHASE ONE Foundation, we are now on the threshold of starting the first ever clinical trials of this new therapeutic approach for the treatment of deadly highly malignant brain tumors. The proposed trial, which was approved by the Food and Drug Administration on April 7, 2011 is currently undergoing the final evaluations by the Institutional Biosafety Committee, and the Institutional Review Board for Clinical Trials. We expect these evaluations to be finalized within the next few weeks. Once our trial has cleared all necessary Committee reviews, it will be ready to start.

PHASE ONE has thus provided the green light to move the dreams of two basic scientists into the challenging arena of clinical trials. As the trial starts enrolling patients we will look forward to keeping PHASE ONE abreast of all therapeutic developments. We hope, and for the sake of the patients, we pray, that treating the first patients may represent in Winston Churchill's prophetic words, *"Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning."*

2010

Children's Hospital Los Angeles

Grant Amount: \$410,000

In February 2010, PHASE ONE granted \$410,000 over two years to fund a Phase I study at Children's Hospital Los Angeles. The study, led by Dr. Stuart E. Siegel, is of AC220 for children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This grant will provide an opportunity in getting a second generation FLT3 inhibitor drug tested in a pediatric population that truly focuses on the concept of FLT3 inhibition in high-risk ALL and AML patients. The goal of the study is to obtain sufficient laboratory and clinical data to enable the design of a larger Phase II study. Results from this study would also leverage funding to support the Phase II part of this project from both the National Cancer Institute, as well as the pharmaceutical company Ambit that makes the drug.

2009

The Premiere Oncology Foundation Lung Cancer Initiative

Grant Amount: \$266,500

Premiere Oncology Foundation, a non-profit dedicated to cancer research, integrative medicine, patient/family support services and community education, will utilize the grant to support a comprehensive lung cancer program to include multi-disciplinary research. Lung cancer is the world's top cancer killer, claiming more than 1.3 million lives per year, yet few financial resources have been dedicated to this disease. The Premiere Oncology Foundation Lung Cancer Initiative focuses on the use of FDA-sanctioned novel treatment regimens in collaboration with experts in the field of lung cancer detection and treatment. The program will foster dialog among practitioners caring for lung cancer patients, and provide a means for seamless interaction with medical and radiation oncologists, thoracic surgeons, radiologists, pulmonologists and primary care physicians caring for these patients.

Dedicated to whole-patient care and recognized for expediting clinical trials, Premiere's flagship cancer center in Santa Monica offers patients the newest cutting-edge treatments, rapid access to novel, internationally available therapies and integrative medicine all under one roof. Additionally, Premiere provides services in its Scottsdale, Arizona center and research affiliation with Pacific Hematology & Oncology Associates in San Diego.

2007–2008

The Samuel Oschin Comprehensive Cancer Institute-Cedars-Sinai Medical Center

Grant Amount: \$2,000,000

Internationally renowned cancer researcher Steven Piantadosi, MD, PhD, was named the inaugural PHASE ONE Foundation Endowed Chair of the Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center at a ceremony February 6, 2008. SOCCI provides cutting edge cancer clinical trials and sub-cellular research, in addition to state-of-the-art patient care. Its research efforts are focused on developing breakthroughs that translate as efficiently as possible into new methods for the treatment of cancers of the lung, brain, colon, prostate, pancreas, breast, spine, ovaries, pituitary, thyroid and blood system, plus melanoma and other cancers.

With this endowment, Dr. Piantadosi will define and direct the activities of the Institute and serve as a key figure in framing the national debate about cancer, while having a decided impact on the direction and success of new research.

City of Hope Comprehensive Cancer Center

Grant Amount: \$345,000

The City of Hope Division of Medical Oncology and its Department of Clinical and Molecular Pharmacology, directed by Yun Yen MD, PhD, is the City of Hope Comprehensive Cancer Center equivalent to a Phase I Solid Tumor Program. In this program is the exciting translation of molecules from the laboratory to the clinic.

City of Hope will use the PHASE ONE funds to support novel Phase I clinical trials developed in collaboration with the Department of Clinical and Molecular Pharmacology. These resources would be utilized to fund novel protocols or existing protocols where additional funds could translate findings from the laboratory to the clinic. Support for novel “NEW” programs (25–50K/year for two years) in Clinical and Molecular Pharmacology that can reach the clinic during the two years of the award, and bring innovation from our laboratories will be the highest priority.

The City of Hope Comprehensive Cancer Center’s Phase I Program has a commitment to the Developmental Therapeutics and Hematologic Malignancies Programs directed by Yun Yen MD, PhD, Richard Jove PhD, and Steven Forman MD. City of Hope will establish competitive awards (25–50K/year for two years) that combine a laboratory and clinical Principal Investigator that translate laboratory observations into the clinic during this period. Programs in Solid Tumors and Hematologic Malignancies including lymphomas, in both adults and children would be included.

2006

Kuk-Wha Lee, M.D. PhD

Grant Amount: \$250,000

Dr. Lee is a graduate of the Medical Scientist Training program at Loma Linda University School of Medicine, obtaining her PhD and MD. Her clinical training is in pediatrics and she was fellowship trained in Pediatric Endocrinology at the Mattel Children’s Hospital at UCLA. In training she was the recipient of the prestigious Giannini Foundation Fellowship, Stein-Oppenheimer Award, and the LWPES Clinical Scholar Award for her research. In addition, she is the recipient of the UCLA Prostate Cancer SPORE Career Development Award for her research in cellular and animal models of human prostate cancer. Her laboratory studies the biological functions of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) and its binding partners in cancer biology, specifically prostate cancer. Specifically, she studies the molecular mechanisms by which this molecule enters cells; targets specific areas within cancer cells (e.g. the nucleus and mitochondria); and initiates the programmed cell death cascade.

Unique assays in their laboratory have been developed to study serum levels of these molecules and also have developed unique transgenic and knockout mouse models of human disease. Based on preliminary work published from their laboratory the plan is to initiate a Phase I trial of IGFBP-3 in men with prostate cancer in the near future.

2005

Karen Reckamp, M.D.—A Phase 1 Trial of Vaccine Therapy with Lung Cancer

Grant Amount: \$500,000

With her mentor, Steven Dubinett, M.D., Director of the UCLA Lung Cancer Program, Dr. Redcamp's efforts are in the immunologic treatment of lung cancer through novel genetic-based immunologic stimulation. Her proposal is for a Phase I Clinical Trial of the intratumoral administration of an immune stimulant called a chemokine to induce an immune response that could yield immunity to this cancer.

2004

Dr. Arie Belldegrun and Dr. Alan Pantuck

Grant Amount: \$250,000

UCLA Department of Urology Specializing in New Treatments for Kidney and other genitourinary cancers, particularly vaccine therapies directed against newly identified targets.

Dr. Heinz-Josef Lenz and Dr. Daniel Vallboehmer

Grant Amount: \$250,000

USC/Norris Comprehensive Cancer Center Specialists in Gastro-Intestinal Malignancy searching for molecular markers to predict prognosis and response to therapy.

Dr. Charles Sawyers and Dr. Ingo Mellinghoff

Grant Amount: \$250,000

UCLA Jonsson Comprehensive Cancer Center Hematology/Oncology Translational Scientists working on molecular mechanisms that underlie the development and spread of cancer.

Dr. David Agus and Dr. Mitchell Gross

Grant Amount: \$250,000

Cedars-Sinai Prostate Cancer Program looking at innovative treatments for prostate cancer and using information technology systems to identify molecular markers for response to therapy.

2003

Dr. Lee Rosen—Cancer Institute Medical Group

Grant Amount: \$276,250

In 2003, Dr. Lee Rosen conducted a Phase I study of a medication that could theoretically shut down the development of new blood vessels from which tumors grow and possibly spread. Using a series of radiographic assessments including CT/MRI/Bone scans, etc. as well as conventional scans such as CT/MRI, Dr. Rosen and his colleagues at the Cancer Institute Medical Group, examined the response of their patients to this new medication and to what degree. He also found the use of PET scans, which look at changes in tumor metabolic activity rather than size, is very effective, PHASE ONE has been sponsoring a trial which will look at whether a combination of PET/CT scans can aid in the assessment of the drug's efficacy more quickly than conventional CT scanning alone.

2002

Dr. Sven de Vos, Dr. Christos Emmanouilides, Dr. William H. McBride and Dr. Jonathan W. Said—Jonsson Comprehensive Cancer Center

Grant Amount: \$150,000

PHASE ONE sponsored an Indisciplinary Grant to study the use of the Proteasome Inhibitor PS-341 in the treatment of refractory diffuse large B-cell lymphomas in terms of clinical efficacy, mechanisms of resistance and new models of combination therapy. The study was conducted by principal investigator, Sven de Vos, M.D., and co-investigators, Christos Emmanouilides, M.D., William H. McBride, M.D. and Jonathan W. Said, M.D. at the Jonsson Comprehensive Cancer Center.

2001

Dr. Carolyn Britten—Jonsson Comprehensive Cancer Center

Grant Amount: \$175,000

PHASE ONE sponsored the recruitment of a full-time clinical research physician for a full year. Highly respected oncologist, Dr. Carolyn Britten, joined the faculty of the Jonsson Comprehensive Cancer Center in early 2001 and PHASE ONE funded her research for one year. Dr. Britten is involved in four promising Phase I trials testing new and unique therapeutic strategies in signal transduction and angiogenesis

WE DO support PHASE ONE

A MESSAGE FROM OUR MEDICAL ADVISORY BOARD

April 30, 2015

Dear Friends,


The Phase One Medical Advisory Board wishes to thank the Board of Directors of Phase One for its vision in supporting the next generation of cancer scientists. The support of investigators whose goal is the translation of discoveries to find better, safer, and more effective treatments for patients with cancer will form the lasting legacy of the Phase One Foundation.

This evening as we celebrate with laughter, entertainment, and fine food, we salute the tireless efforts of this young and spirited organization. Since 1999, Phase One has raised over \$15 million for cancer research, funded more than a dozen research programs, and equally as important has created greater awareness in our community about the importance of funding clinical trials and investigative studies.

All of us on the Medical Advisory Board are very proud of achievements like this. But we are also always aware of how much more has to be accomplished before we can say, "We are indeed curing cancer."

Because of the generosity of all of you with us tonight, the task is made easier. Thank you for giving us the opportunity and for your all-important support of Phase One.

Sincerely,

A handwritten signature in black ink, appearing to read "Robert A. Figlin". The signature is fluid and cursive, with the first name "Robert" and last name "Figlin" clearly legible.

Robert A. Figlin, MD., FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center

WE DO support PHASE ONE

MEDICAL ADVISORY BOARD



Robert Figlin, M.D. F.A.C.P.

Robert Figlin, M.D. F.A.C.P. is the Associate Director of the Academic Development Program and Director of the Division of Hematology/Oncology at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. He is board-certified in both medical oncology and internal medicine. Dr. Figlin previously served as Professor and Chair of the Department of Medical Oncology and Therapeutic Research at City of Hope. He also was affiliated with the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles (UCLA) for more than 20 years, where he held a number of leadership positions in the areas of urologic cancer, hematology/oncology and thoracic oncology.

Dr. Figlin is a prolific researcher known for advancing urologic and lung cancer therapies. His expertise has resulted in the development of novel anti-cancer drugs that have led to improved outcomes for patients. Dr. Figlin has written more than 300 peer-reviewed publications, authored several books on kidney cancer and published more than 60 book chapters on new approaches to cancer treatment. He is a fellow of the American College of Physicians and the International Society for Biologic Therapy as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, the National Comprehensive Cancer Center Network and the American Urological Association. Dr. Figlin earned his bachelor's degree in chemistry from Temple University where he also earned a graduate degree in organic chemistry. He earned his medical degree from the Medical College of Pennsylvania. Dr. Figlin served his internship and residency at Cedars-Sinai Medical Center where he was Chief Medical Resident and completed a fellowship in hematology/oncology at UCLA.



Stephen J. Forman, M.D.

Dr. Stephen Forman has been Chair, Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center and Program Director, Hematologic Neoplasia, City of Hope Comprehensive Cancer Center since 1987. He first joined City of Hope in 1979 after completing a fellowship there. He did his undergraduate studies at St. John's College, Annapolis, Maryland and attended medical school at the University of Southern California. In addition to serving on the Phase One Medical Advisory Board, he is a member of the Scientific Advisory Board for the Cure for Lymphoma Foundation, a member of the Scientific Subcommittee of Transplant Biology for The American Society of Hematology, Chairman of the Marrow and Stem Cell Committee for the Southwest Oncology Group, and a member of the Gene Therapy Advisory Council, City of Hope and Beckman Research Institute.



Philip H. Koeffler, M.D.

Dr. Philip Koeffler is a Professor of Medicine at UCLA School of Medicine and is Director of the Division of Hematology/Oncology at Cedars-Sinai Medical Center. He did his undergraduate training at the University of Wisconsin, Madison and then attended Baylor College of Medicine for Medical School Training. He completed his internship and residency at the University of Southern California, and his fellowship in Hematology/Oncology at UCLA. He went through the professorial ranks from Assistant Professor to Full Professor at UCLA from 1978 to 1986, and in 1992, he moved his laboratory to a large research area at Cedars-Sinai Medical Center. He has over 600 peer-reviewed scientific articles published or in press and over 75 chapters in medical scientific books. Dr. Koeffler uses cellular and molecular biology to ask cancer-related questions. He has large tissue banks for many different cancers including brain, breast, lung and leukemias and lymphomas. He has well over 100 different cancer cell lines frozen viably and at any one time perhaps 30 of these cell lines are growing in the laboratory. In addition, he frequently uses mice (nude, transgenic, and deletional). Some of his major accomplishments include: being the first lab to identify p53 to be mutated in human cancer; being one of three labs to identify p53 as a transcription factor; developing one of the first human myeloid leukemia cell lines (KG-1) which has over the years has become a model to study leukemia (these cells were used to clone, for the first time, the alpha interferon gene and to make the CD34 antibody which has been used to purify hematopoietic stem cells); being first to develop a cell line (KS-1) infected with Kaposi's Sarcoma associated virus (HHV-8), but not infected with either Epstein Barr Virus or human immunodeficiency virus; being first to clone cyclin A1, a protein involved in cell cycle progression and performing experiments to understand the protein's biology; being first to clone and study transferrin-2 and receiving a patent on various aspects of this protein.

which is important in iron metabolism, and if mutated, causes hemochromatosis; being first to clone a myeloid transcription factor known as C/EBP, a protein critical for myeloid (white) cell development (Dr. Koeffler's lab was one of two labs to first identify the genetic abnormality in patients with "Specific Granule Deficiency" disease – germline mutation of C/EBP and one of two labs first to identify mutations in C/EBP in acute myelogenous leukemia. He also noted that the gene was silenced in a number of other cancer subtypes, a discovery that lends itself to become a therapeutic target).



Heinz- Josef Lenz, M.D.

Heinz-Josef Lenz, M.D., is a Professor of Medicine and Professor of Preventive Medicine in the Division of Medical Oncology at the Keck School of Medicine at the University of Southern California (USC). He is Co-director of both the Colorectal Center and the Gastrointestinal (GI) Oncology Program, as well as is Scientific Director of the Cancer Genetics Unit at USC/Norris Comprehensive Cancer Center in Los Angeles. Dr. Lenz received his medical degree from Johannes-Gutenberg University in Mainz, Germany, in 1985. He completed a residency in hematology and oncology at the University Hospital Tübingen in Germany, a clerkship in oncology at George Washington University Medical Center in Washington, D.C., and a clerkship in hematology at Beth Israel Hospital of Harvard Medical School in Boston, Mass. He served subsequent fellowships in biochemistry and molecular biology at the Norris Comprehensive Cancer Center. An active researcher, Dr. Lenz focuses on topics including the regulation of gene expression involved in drug resistance, patients at high risk of developing colorectal cancer, determination of carcinogenesis, and methods of early detection and better surveillance of these cancers. He is a member of several professional societies such as the American Association for Cancer Research, American Gastroenterological Association, and National Society of Genetic Counselors. He also serves on the national advisory board of a number of professional organizations. A Fellow of the American College of Physicians, Dr. Lenz is the author of numerous peer-reviewed publications and invited papers, reviews and editorials. In addition to having a National Cancer Institute-funded laboratory, he is a recipient of the American Society of Clinical Oncology (ASCO) Young Investigator Award, ASCO Career Development Award, and the STOP CANCER organization's Career Development Award. He has been listed in the BestDoctors.com database since 2003.



Frank L. Meyskens, Jr., M.D., F.A.C.P.

Dr. Frank Meyskens is Professor of Medicine and Biological Chemistry, Director of the Chao Family Comprehensive Cancer Center, and Senior Associate/Dean of Health Sciences for the College of Health Science at UC Irvine. He was originally recruited to UC Irvine in 1989 as Professor of Medicine and Biological Chemistry and to serve as Medical Director of Oncology Services and Chief of Hematology/Oncology with the mandate to develop a Cancer Center. He received his M.D. and interned at the University of California, San Francisco, and completed his Medical Oncology training at the National Institutes of Health, during which time he conducted molecular biology investigations in the Laboratory of Tumor Cell Biology. Since 1977, he has been continuously funded by the National Institutes of Health. Prior to UCI, Dr. Meyskens was at the Arizona Cancer Center at the University of Arizona where he served as Associate Director of Cancer Prevention and Control, from 1984 to 1989, and established one of the most successful Cancer Prevention Research Programs in the world. While at Arizona, he was Principal Investigator of the Vitamin A and Chemoprevention Program Project (PO1 CA 27502) and the PO1 CA41108 Program Project for the study of colon cancer and prevention. He has established a similar chemopreventive effort at UCI and is conducting phase I, II, III and IV chemopreventive trials supported by the NCI and NIH. His current major efforts also include accrual to a phase IIb trial of Bowman-Birk Inhibitor in oral leukoplakia, a phase IIb/III cohort of patients at risk for colon polyps treated with DFMO plus sulindac versus placebo, and a unique natural history, epidemiology and chemoprevention study of patients at high risk of prostate cancer based on familial background. All studies have extensive translational components and are funded by the National Cancer Institute. Additionally, for over 25 years he has conducted active clinical and laboratory research into the cellular and molecular mechanisms of transformation of human melanocyte and melanoma cells and he is recognized as one of the premier clinical and experimental oncologists concerned with melanoma.

WE DO support PHASE ONE

CANCER RESOURCES

Phase One Foundation
(310) 458-7715
www.phaseonefoundation.org

A Fresh Chapter
www.afreshchapter.com
fcaf@afreshchapter.com

Tia's Hope
www.tiashope.org
info@tiashope.org

American Cancer Society
(800) 227-2345
www.cancer.org

**John Wayne Cancer Institute
at Saint John's Hospital and Health Center**
(800) 262-6259
www.jwci.org

**Cedars-Sinai
Samuel Oschin Comprehensive
Cancer Institute**
(310) 423-8030
www.cedars-sinai.edu

**UCLA Jonsson
Comprehensive Cancer Center**
(310) 825-5268
www.cancer.ucla.edu

Chai Lifeline
(877) 242-4543
www.chailifeline.org

**USC/Norris
Comprehensive Cancer Center
and Hospital**
(800) 872-2273
(323) 865-3000
<http://uscnorriscancer.usc.edu>

**Children's Hospital Los Angeles
Children's Center
for Cancer & Blood Diseases**
(323) 669-2121
www.chla.org

**Vital Options International:
"The Group Room"**
(818) 508-5657
www.vitaloptions.org

City of Hope
(626) 359-8111
www.cityofhope.org

**Cancer Support Community
Benjamin Center
(formerly The Wellness Community)**
(310) 314-2555
www.cancersupportcommunitybenjamincenter.org

**Pancreatic Cancer Action Network
(PanCAN)**
(310) 791-5214 or (877) 272-6226
www.pancan.org

• • •

15 YEARS...15 GALAS

Visit our Facebook Page ([PhaseOneLA](#)) and website ([phaseonefoundation.org](#))
for photos from past events

2000

L'Ermitage Beverly Hills
Chair
Stacy Valner

2001

Cicada Downtown Los Angeles
Chair
Diana Nathanson

2002

Four Seasons Beverly Hills
Chair
Janet Lonner

2003

Four Seasons Beverly Hills
Chair
Marc O. Foster

2004

Beverly Hills Hotel
Co-Chairs
Dana Asher
Lisa Gores

2005

Hangar 8 at the Santa Monica Airport
Co-Chairs
Nancy Newberg
Tia Palermo Ravich

2006

Regent Beverly Wilshire Hotel
Co-Chairs
Dana Asher
Lisa Gores

2007

Beverly Wilshire Four Seasons Hotel
Co-Chairs
Laurie McCartney
Erica Wertheim Zohar

2008

Beverly Wilshire Hotel
Co-Chairs
Laurie McCartney
Missy Polson
Julie Sachse
Anna Suddleson

2009

Phase One "Non-Event"

2010

SLS Hotel & The Bazaar
Co-Chairs
Tia Palermo
Missy Polson

2011

SLS Hotel & The Bazaar
Chair
Tema Schrage

2012

Montage Beverly Hills & Bouchon Bistro
Co-Chairs
Marina Cohn
Mieke Neumann

2013

Montage Beverly Hills & Bouchon Bistro
Co-Chairs
Marina Cohn
Mieke Neumann

2014

Montage Beverly Hills & Bouchon Bistro
Co-Chairs
Angela Kay
Stephanie Sandler

2015

Wallis Annenberg Center for the Performing Arts
Co-Chairs
Meritt Elliott
Stacy Valner

WE DO support PHASE ONE

HEARTFELT THANKS

Albert & Holly Baril	Kaye Popofsky & Jeremy Kramer
Camille Bergher	Mira & Brian Lee
Royce & Ashleigh Bergman	Jody & David Lippman
Bari & Fred Bernstein	Lonner & Kurtzman Families
Emily & Jordan Bernstein	Alyson & Ori Marmur
Dorian Bilak	Katie McGrath & JJ Abrams
Bernard & Judy Briskin	Marla & Brett Messing
Cedars-Sinai Medical Center	Milken Family Foundation
Cherokee Global Brands	Kathryn & Sam Naficy
Marina & Adam Cohn	Mieke & Spencer Neumann
Carly & Alejandro de Castro	Nancy & Bruce Newberg
Disney Company	The Newman Foundation
Diane & Roger Duhl	Kathy & Joe Pretlow
Jill Roberts & Mark Freeman	The Ravich Family
Maryann & Irwin Gold	Eden & Steven Romick
Ron & Betty Goldie	Ellen & Richard Sandler
Elizabeth Goldhirsh	Stephanie & Nicholas Sandler
The Goldhirsh-Yellin Foundation	Amie & Asif Satchu
Laurie & Christopher Harbert	Reagan Silber
Martha & David Ho	Topson Downs
Martha & Bruce Karsh	Stacy & Alberto Valner
The Kayne Foundation	Edward & January Woods

Our sincere gratitude to those whose generous contributions reached us after press time

WE DO support PHASE ONE

Thank you

Meritt & Stacy

• • •

PHASE ONE
BOARD OF DIRECTORS

To our Dedicated Team

The Dinner Committee

Holly Baril
Emily Bernstein
Leslie Birnbaum
Marina Cohn
Leanna Creel
Emily Current
Natalie Fair
Jill Roberts Freeman
Alyson Fine Marmur
Marcy Foster
Maryann Gold
Angela Kay
Kaye Popofsky Kramer
Brooke Lande
Dana Levine
Janet Lonner
Zoe Ravich McNitt
Linda Meadow
Mieke Neumann
Elissa Phillips
Missy Polson
Kimberly Reed
Stephanie Sandler
Tema Schrage
Debra Silverstein
Anna Suddleson
Suzette Swalwell
Alyssa Weinberger

We thank you for all your hard work, inviting all your friends,
attending meetings, and inspiring us with creative ideas
to make the Gala a success.

And special thanks to

Meg Noyes
Ariella Masjedi
Lindsey Bledsoe
for making the Mystery Gifts look beautiful!

Meritt & Stacy

Edyn Elliott Barber

Thank you for creating our logo and invitations!

• • •

FUN FACT

Edyn gave birth the night the invitations were complete!



2 jobs well done!!

Thank you!!!

• • •

Meritt and Stacy

Debbie and Leslie

Mystery Gift Fearless Leaders

We thank you helping us raise
additional funds tonight
to fight cancer and
ensuring that it is FUN!

...

Meritt and Stacy

Maryann & Suzette

*Thank you for making our vision
become a reality tonight at the
Wallis Annenberg Center*



Thank you

Leanna Creel and Meritt Elliott

and to your team

Aaron Anderson
Evan Barthleman
Miranda Campolo
Maureen Flannigan
Ross Grant
Rinat Greenberg

Tracy Hof
Mandy Moore
Heather Petrone
Noah Philipps-Edwards
Heather Reid

for another incredible video and
for showing us – so beautifully – that
YOU DO support **PHASE ONE!**

• • •

We especially want to thank
Ashley Walton
for sharing your story with us

and in loving memory of
Kristine Reid

• • •

PHASE ONE BOARD OF DIRECTORS

Marci and Greg Foster

• • •

Thank you for never saying
“I CAN’T” to Phase One!

Your kindness and generosity to
Phase One is never ending.

Every time we see a Phase One Hat
in the community
we will think of you!!!

• • •

Stacy and Alberto

Meritt and John

Lissa,

The words
“YOU DO” support Phase One
have never been more true.
Patience, dedication, understanding,
referee and support
are all words that describe all you do for us!

Thank you for all you “do” always.

Stacy and Meritt

franci

For all your hard work

we are GRATEFUL!

• • •

Meritt & Stacy

gold wong photography

*Thank you so much
for capturing the special moments
of our event.*

PHASE ONE BOARD OF DIRECTORS

CURE

• • •

WE DO support PHASE ONE

WE DO support PHASE ONE

**and are proud to stand with them
in the fight against cancer
and the hope for a cure!**

Judy & Bernie Briskin



IT TAKES EACH OF US TO MAKE A DIFFERENCE FOR ALL OF US.

Cedars-Sinai is proud to partner
with PHASE ONE on cutting-edge
research in the fight against cancer.

Congratulations on your
15th anniversary.



CEDARS-SINAI

©2014 CEDARS SINAI

Mummy,

We are so proud of everything you do
to help find a cure for cancer.
You're the best Mummy on the planet
and we love you so much!

Love,
David, Charles & Aerin
xoxoxo

WE DO

• • •

The Kramer Family

Kaye, Jeremy, Maxime, Jules and Oscar

Marina,

Thank you for your tireless dedication to
PHASE ONE!

Love,
Mieke and Spencer

We are proud to support Phase One
and congratulate our dear friend

Stacy

for her dedication to this important cause.

With love,
Nancy and Bruce Newberg

TOPSON DOWNS



TOPSON DOWNS SAYS, "I DO"
TO SUPPORTING PHASE ONE.

ELWOOD®

love.
FIRE

RACHEL ROY

T I N S E L T O W N
D E N I M C O U T U R E

We are grateful to be able
to support an organization
which funds some of the
best and brightest
medical researchers
on the cutting edge of
cancer discoveries.

...

January and Eddie Woods

LIFESAVER

• • •

WE DO support PHASE ONE

**WE ARE PROUD TO SUPPORT
PHASE ONE.**

**KATIE MCGRATH & J.J. ABRAMS
FAMILY FOUNDATION**

• • •

IN MEMORY OF TIA PALERMO

WE ARE PROUD TO SUPPORT
PHASE ONE
IN YOUR EFFORTS TO FIND A CURE.



ASPIRATION. INNOVATION. SCALE.

**CHEROKEE
GLOBAL
BRANDS**

We salute Phase One
and its amazing accomplishments.

...

Susan Vann Kurtzman & Rick Kurtzman
Sharon Klein & Howard Kurtzman

WE DO

*commit ourselves in continuing to be a part
in making a difference until a cure is found!*

WE DO

*celebrate everyone who works so hard for
Phase One!*

• • •

Janet & David Lonner



We recognize and celebrate
Marina Cohn
and the other
Board and Committee members
for their passion and commitment
in supporting
Phase One
clinical cancer research programs



**MILKEN FAMILY
FOUNDATION**

Leading Advances in
Education and Medical Research

To my Queen

You are the keeper of all things beautiful in our family.
Your dedication to art, life, and love inspires us every day.
We are truly thankful for your boundless compassion
and infinite wisdom.

Love,
Dada, Lyric, and Wolfe



Mommy,

15 years hasn't aged PHASE ONE (or you) one bit!

Congratulations on an amazing event.

We love and are beyond proud of you.

All of our love

Lucy, Sophia, Harry, Niki



DADDY

YOU ARE OUR HERO

YOU MAKE OUR DREAMS COME TRUE

STACY

SOPHIA NIKI HARRISON LUCY

2015

Three years without Tia is three years too many.



We miss you every day.

Stacy & Alberto



In loving memory of
Kevin Carlberg

The Board of Phase One

*In memory of
Marilyn Silverstein*

Phase One Board of Directors

Always in our hearts.



*Alberto, Stacy, Sophia, Nicole,
Harrison, and Lucy*

HEALER

• • •

WE DO support PHASE ONE

*Thank you to all
who have helped us
follow the science and funded a
Phase One clinical trial.
Together we will cure cancer
one therapy at a time!*

*Love,
Holly, Albert,
Alexandra & Graydon Baril*

I DO

**Support and Applaud all the Achievements
Phase One Foundation
Has Made Over the Past 15 Years**

**Here's to the Next 15 Years and
Finding Success in the Researchers and Trials
We Fund**

• • •

**Royce & Ashleigh & Greyson
and Emily Bergman**

**AMANDA BROWN &
JUSTIN CHANG**

**ARE PROUD TO SUPPORT
PHASE ONE**

In Loving Memory of
Meg Mazursky

...

Carly & Alejandro de Castro

F*\$% CANCER

JILL ROBERTS-FREEMAN AND MARK FREEMAN

**Cancer is a beast
and we support the efforts of
Phase One and all those that work
to beat that horrible beast
into submission!**

• • •

Betty and Ron Goldie

You're still the One!

xo

The Harbert Family

We are so proud to be part of the
PHASE ONE family.

Thank you to

MERITT & STACY

For putting together
this year's amazing event

...

ALYSON & ORI MARMUR

Stacy,

Your passion & commitment to Phase One
have been an inspiration to us all.

Thank you for all that you do.

Love,
Cary, Linda, Sarah, Eve & Ruby

*Thank you
Phase One,
for all the great work you do!!*

• • •

The Messing Family

*We are proud to support the
extraordinary work of
Phase One.*

*We're grateful to the Board and Event Committee
for all their hard work and dedication.*

*With love,
Sabina and David Nathanson*

WE DO SUPPORT PHASE ONE

The Newman Foundation

We are proud to support

Phase One

and the continued

search for a cure.

Eden and Steven Romick

IT IS A PRIVILEGE TO HONOR
THE OUTSTANDING WORK OF PHASE ONE
AND TO CONGRATULATE ITS CHAIR,
MARINA COHN,

OUR DEAR FRIEND,
STEPHANIE SANDLER,

AND THE REST OF THE BOARD OF DIRECTORS.

• • •

ELLEN, RICHARD & TRACY SANDLER

*We are proud to support Phase One.
Here 's to finding a cure.*

Stephanie and Nicholas Sandler

Phase One is
Fighting and Winning the Good Fight!

Congratulations to you all and to our beloved

Mieke

The Schechter Family

CONGRATS TO PHASE ONE
FOR ALL THE GOOD WORK
YOU DO.

REAGAN SILBER

Tia

You are always in our hearts

With all of our love,

...

Orna and Keenan Wolens

WELLNESS

• • •

WE DO support PHASE ONE

For the
children

ACTIVISION® | BLIZZARD®

Congratulations

...

Lynn & Les Bider

Thank you!




BOOMTOWN

BREWERY

ARTS DISTRICT LOS ANGELES

Phase One Board of Directors



more TOMORROWS start HERE

City of Hope is a comprehensive cancer center and independent biomedical research institution committed to curing cancer, diabetes and other life-threatening diseases. Here, our scientists, doctors, nurses, staff and volunteers work together to save lives today – and tomorrow. Together, we are transforming the future of health.

We are grateful for the support of Phase One, which allows us to create more tomorrows for patients and their families – here and across the globe.



City of Hope®

RESEARCH • TREATMENT • CURES



WWW.CITYOFHOPE.ORG

In loving memory of
Kelly Romick

• • •

Kate and Jeff Colin

In appreciation for the years of research
which has led to the diagnosis and recovery
of my daughter
Eileen Coskey Fracchia
and to
David and Janet Lonner
for their dedication to the work of Phase One.

• • •

Rhea Coskey

THE DAVIDOW CHARITABLE FUND
PROUDLY SUPPORTS PHASE ONE

Marcí & Greg Foster

*We treasure our friendship,
and proudly admire your devotion to
Phase One -
a reflection of your
generosity and compassion*

*With love,
Marcí & Jeff Dínkín*

FALCON SPIRITS

DISTILLERY



*Thank you for
supporting Phase One*

Marina

Your courage, strength and vision
inspire us all.

May you continue
your great work for

PHASE ONE

With love,
Cynthia & Ralph Finerman
Pam & Stan Maron

Thank you for supporting PHASE ONE



PHASE ONE BOARD OF DIRECTORS

Fleury Estate Winery
950 galleron rd.
rutherford, ca
p. 707.967.8333
info@fleurywinery.com

We salute the efforts of
PHASE ONE
to find the cure

We congratulate
Mark and Jill Freeman
for their efforts

• • •

JUDY AND LARRY J. FREEMAN

Congratulations to
Phase One
and the
Meadow/Valner Families
on creating a lasting legacy of
compassion and research!

• • •

***Lori, Simon &
Charlotte Furie***

We Do

Support

PHASE

ONE...

HELD
FOUNDATION

THE POWER OF GIVING. THROUGH THE GENERATIONS

The Lacine and Joseph Held Family

The Lisa and Robert Held Family

The Melissa Held Bordy Family

Stacy and Alberto

Thank you for championing such a great cause and
bettering the lives of so many.

• • •

Sandy and Jeff Hudson

Congratulations
PHASE ONE
on an incredible 15 years.
Here's to the next phase of the journey...
I DO!

...

Angela Kay & Michael Richards

The Kay Family says
I DO
to Phase One!

Congratulations to
Stacy, Meritt, Angela
and everyone at Phase One
for their hard work and dedication.

Cindy and Jerry Kay
Courtney and Andrew Kirsh
Michael Richards

Thank you

Richard & Kathy Leventhal

...

Phase One Board of Directors

Thank you

Marina Cohn

and everybody at

Phase One

for your hard work and extreme dedication

to this very important cause!

...

Andrea and Jason Lublin

Stacy and Alberto –

For the past 15 years, your dedication to cancer research
has been an inspiration to all of us.

We are so proud of you both – and proud to say

WE DO support PHASE ONE!

• • •

Mary & Steve

We are proud to support
the important work of

PHASE ONE

and congratulate

Marina Cohn

for her amazing efforts!

Sarah and Jeremy Milken



CONGRATULATIONS
TO ALBERTO & STACY
FOR ALL THE
WONDERFUL WORK
THEY DO FOR
THEIR COMMUNITY.

Elaine & Trevor Pearlman



We are proud to support
such a great cause.

Thank you Eddie Woods
for the introduction.

~

John and Audrey

Stacy and Meritt,

Congratulations on a
fabulous and successful event!

And thank you to our incredible
friends and family
who have supported Phase One!

...

The Polson Family
Missy, Glen, Scotty, Brett and Matty

Special thank you to
Leah Radow
an incredible, caring student at
Paul Revere Middle School's
Eco Homeroom.

She organized a bake sale, with the
“Go Green” club and sponsor Ms. Chen,
to benefit Phase One and cancer research!

The future is in great hands with
young people like you!

• • •

PHASE ONE BOARD OF DIRECTORS

Congratulations to all our friends
at PHASE ONE for all of their
remarkable work.

...

Sheri & Marc Rapaport

Thank you to Phase One
for your continued progress
in finding a cure for cancer.

Patty and Michael Rosenfeld

*We are pleased to support
Phase One.*

Harriet & Eric Rothfeld

Stacy and Alberto –

Look what you started!
15 years of giving
15 years of research
15 years of advancement
in the war against cancer!

We're so proud!

With love,
Frankie and Barry Sholem
Cece and Bill Feiler
Heidi and David Haddad

We are proud to support

PHASE ONE

and the tireless efforts
of so many in search of a cure


...

Carolyn and John Tipton

*We honor Holly and Albert
for all of their charitable work!*

*Our love,
Stephanie and Leon Vahn*

Thank you for your support



PHASE ONE BOARD OF DIRECTORS

BELIEVER

• • •

WE DO support PHASE ONE

*How wonderful it is that nobody need wait a single moment before
starting to improve the world.
~ Anne Frank ~*

Royce -

You never waste or wait a single moment to help others. We are proud of your contributions to Phase One and grateful for all that you do for us.

Lise & Rob Applebaum

We are happy to support the good work of Phase One

■ ■ ■

Gail and George Baris

WE DO support PHASE ONE

&

ALLIE NEWMAN

...

THE BECKERMAN FAMILY

In honor of Kelly.

We continue to fight to find a cure.

Chet and Donna

*Congratulations to all our friends who work
so tirelessly on behalf of Phase One.*

Lisa and Jordan Bender

IN LOVING MEMORY OF
LINDA BERNSTEIN

AND

IN APPRECIATION OF
PHASE ONE

• • •

*THE BERNSTEINS
JONATHAN, JESSICA,
JORDAN, EMILY AND MARSHALL*



LYNNE COHEN FOUNDATION

Lynne Cohen Foundation is proud to partner with Phase One to support Dr. Sanaz Memarzadeh's groundbreaking research.

TOUCHING WOMEN'S LIVES.
FIGHTING WOMEN'S CANCERS.

**WE CONGRATULATE OUR FRIENDS,
EDDIE AND JAN WOODS,
FOR BEING INVOLVED WITH PHASE ONE
AND THE GREAT WORK THEY ARE DOING.**

...

**MUCH LOVE,
SHELLEY AND MARTY COOPER**

Dear Mieke and Spence –
We support your support of Phase One.

Love,
Julie and Roger Corman

**In recognition of
Stacy and Alberto Valner
for all of their passionate dedication to
PHASE ONE**

...

Jaye and Neal Eigler

Thank you Phase One
With appreciation and gratitude

• • •


Quinn and Bryan Ezralow

Congratulations to
Marina
for all of her hard work for
Phase One.

...

Judy and Jerry Felsenthal

**LAURA FOX AND BEN VAN DE BUNT
ARE PROUD TO SUPPORT
THE INCREDIBLE WORK OF
PHASE ONE**



Megan, Alexander and the Gaon Family
wish to take this opportunity to thank
the greatest doctors in the world –
Dr. Allen Chan, Dr. Allen Ho,
Dr. Shahrooz Eshaghian and Dr. Bob Leibowitz –
for all they have done for us.
We love you from the bottom of our hearts and
appreciate the impact you have had on our lives.
Thank you for all the love and dedication
you have shown to me and my family.

*In memory of Tia Palermo,
and in honor of our many friends
who lead Phase One
with their hard work and commitment,
we are proud to support Phase One.*

• • •

Priscilla and Jamie Halper

We are proud to support

Phase One

and we congratulate all the honorees
at this year's gala.

HERTZ LICHTENSTEIN & YOUNG, LLP
ATTORNEYS AT LAW

Missy Polson and the entire Phase One team,

*We are so proud of and thankful for
your continuous dedication and
involvement with
Phase One!*

*Love always,
Jen, Andy, Josh, Ryan and Brooke Howard*



Private Client Advisors

***Congratulates the PHASE ONE Board of Directors
for their exceptional work and commitment to curing cancer***

Todd Van Donge, Senior Vice President – HUB International/Private Client Advisors
700 S. Flower Street, Suite 1520, Los Angeles, CA 90017
Direct: 213-996-4006 Mobile: 213-926-7220 Fax: 323-686-5409 License #: 0745713
Email: todd.vandonge@hubinternational.com

Stacy & Alberto Valner



Your dedication to Phase One

has impacted the lives of so many.

You're an inspiration to us and your community.

We wish you continued success!

~ Leslie Weisberg & James Hyman ~



Marina, Leslie & Roger,

Congratulations on all your hard work!

XO,
Julie Jaffe

Congratulations to Phase One
for everything you do!

...

Mary and Dan James

**Thank you,
Phase One!**

**We are inspired by your leadership
in support of innovative research.**

• • •

Meredith and David Kaplan

Stacy...
You're the best !

Love
Susan and Jonathan Krane

We are in support of
Phase One's dedication
towards fighting cancer.

• • •

Best wishes,
Les & Cyndy Lederer

To Stacy and Alberto,

Here's to all the Phases of our lives that we have
shared together.

We love you,

Dana and David Levine

LET'S TURN THE "C" WORD
INTO A GOOD WORD!

HELP FIND A CURE FOR CANCER

THANK YOU TO MISSY, GLEN, CAMILLE & MANUEL
FOR INVITING US TO BE PART OF THIS EFFORT.

CARLA, ROD, AVA & SAMANTHA LIBER

We are honored to be a

longtime partner with

Phase One

and support them

on their unrelenting

fight against cancer.

LONGO
TOYOTA

(800) 579-9586
longotoyota.com
3534 North Peck Road
El Monte, CA 91731

LONGO
SCION


(800) 579-9586
longoscion.com
3534 North Peck Road
El Monte, CA 91731

LONGO
LEXUS

(800) 566-3759
longolexus.com
3530 North Peck Road
El Monte, CA 91731

Great Selection, Great Service, Great People, Everyday!
Why go anywhere else?





Stacy
Congratulations!

You and your family's commitment
make us proud to be a part of
PHASE ONE

Love,
Laurie, Jack and Ally McCartney

Congrats to Alberto, Stacy and Phase One's many leaders
on the hard work that turned
an idea into a remarkable 15 year run!

We are so proud of you and honored to be a part of
Phase One.

Brad, Jodi and Leo Meadow

We are proud to support Phase One

...

The Hirsh ~ Naftali Family

Congratulations to

Steve Romick

for your important work with Phase One

...

The Nathan Family

THANK YOU
PHASE ONE
AND OUR FRIEND
MARINA COHN
FOR YOUR EFFORTS
ARE CHANGING LIVES
HEDY & BENJAMIN NAZARIAN

**MARINA,
WE LOVE YOU!
MELANIE & MIKE**

You are never too young to join the fight against cancer

• • •

The Newman Foundation is proud to support Phase One
and help build new youth projects

*Congratulations to all of our friends
dedicated to making a difference!*

• • •

Liz and Michael Nyman

**Congratulations to Stacy & Alberto
and the whole Phase One Board
on 15 great years!**

• • •

**Love,
Elissa, Rick, Alexis, Spencer & Holden**

**We are proud to support PHASE ONE
and the important work that you do.**

• • •

Lyle and Lisi Poncher

Thank you

Marina

for your tireless efforts
in support of cancer research

Tammy & Richard Ratner

NICOLE SASSAMAN

salutes the Phase One Foundation for their
unwavering commitment to cancer research.

NICOLESASSAMAN.COM

BRANDING DESIGN BY FLAT 6 CONCEPTS

*Congratulations to Marina & Jordan
on another successful event!*

~

Bella & Rafael Shpelfogel

WE ARE PROUD TO SUPPORT THE
GREAT WORK OF PHASE ONE

• • •

JASON AND EMBETH SLOANE

We are proud to support Phase One
and the incredible work they are doing.

Irene and David Smith

*Susan Sullivan & Connell Cowan
are proud to say...*

WE DO support PHASE ONE

WE DO SUPPORT PHASE ONE
AND ALL THE LIVES IT WILL SAVE.

THE SWALWELL FAMILY

*Congratulations to Phase One
for the wonderful work that you do.*

Mary Ann Weisberg & Bryce Perry

WE SALUTE HOLLY AND ALBERT BARIL
IN THEIR COMMITMENT TO FINDING A CURE!

• • •

WITH ADMIRATION,
JENNIFER AND RANDY WOOSTER



Mom,
We miss your smile
everyday.

Love,
Nancy & Lissa

Eddie,
If it's important to you,
it's important to me.

XX,
Mistech

THANK YOU TO
PHASE ONE
FOR FIGHTING TO ERADICATE CANCER.

• • •

A SPECIAL THANK YOU TO
MARINA COHN.
WE ARE SO PROUD OF YOU.

• • •

DAYLE AND ABE ZUKOR

Carol and Rand April
are proud to support

Phase One

in its efforts to fight cancer.

*With love to
Jordan & Emily
Bernstein*

The Colmans

TO ALL OUR FRIENDS
WHO HAVE WORKED
FOR
15 YEARS TO MAKE
PHASE ONE
SUCH A SUCCESS

CONGRATULATIONS!!
KEEP UP THE
GREAT WORK!

**NANCY & MIKE
EISENSTADT**

I believe your spirit

Tia

will comfort and aid
those who need your
care and love.

Mimi Ravich



SRC SBC
SHIRLEY'S SHIRLEY'S
BOUTIQUE & CONSIGNMENT

We are proud to
support this
worthy cause!
Shirley & Lou Shapiro

760-773-4800

Shirley's Boutique &
Consignment
72171 Hwy 111 #200
Palm Desert
(at parents' path / Above canyon design)

STATE NARROW FABRICS

Worldwide Manufactures of Elastics

323-232-8881

WE DO support PHASE ONE

SPECIAL THANKS

Adidas
AEG Facilities
Akasha Restaurant
Alimento Restaurant
Diane Allen
Wallis Annenberg Center for
Performing Arts
Dana Asher
Katie B. Photography
Bandalier
Edyn Elliott Barber
Holly Baril
Barry's Bootcamp
Beats by Dr. Dre
Royce Bergman
Emily & Jordan Bernstein
Beauty Undercover
Beyond Yoga
Leslie Birnbaum
Franci Blattner
Lindsey Bledsoe
Boomtown Brewery
Bottega Louie Restaurant
Bouchon Beverly Hills
Calabasas Catering
Cheeky's Restaurants
Cherokee Global Brands
Church & State Restaurant
Marina Cohn
Comoncy
Coral Tree Café
Leanna Creel
Anne Cronin Photography
Emily Current
Carly de Castro
DryBar
Meritt Elliott
El Encanto
Exsel Inc.
Falcon Spirits

Brian Fleury
Fleury Winery
Flywheel
Marci & Greg Foster
Four Seasons Resort &
Biltmore Hotel
FTA Events & Marketing
Cindy Gold
Gold/Wong Photography
Maryann Gold
Dana Goldberg
Gracias Madre
Gratus
Rinat Greenberg
Healthy Spot
Carolina Herrera
Illume Spa
IMAX Entertainment
Jerry's Deli
Lee Jossel
Jouer Cosmetics
Juice Served Here
Thomas Keller Restaurant Group
La Dolce Vita
Helmut Lang
Richard Leventhal
Lifespring Bodywork
Locanda del Lago
Ariella Masjedi
Brad Meadow
Milo & Olive Restaurant
Milly & Li Jewelry
Montage Laguna
Moonshadows Restaurant
Neiman Marcus
Bob & Kelly Newman
Meg Noyes
Sylvia Olson
Paige Denim

Elissa Phillips
Porta Via
Pressed Juicery
Micki Puopolo
John Rankin
Jess Ravich
Zoe Ravich McNitt
Red Room
Jill Roberts & Mark Freeman
Lauren & Anton Schiff
Ava Shambam, M.D.
Silk'n Home Skinovations
Debbie & Rob Silverstein
Anne Sisteron Fine Jewelry
SoulCycle
Sprinkles Cupcakes
Staples Center
Henry Stupp
SugarFISH
The Sunset Restaurant
Suzette Swalwell
Tempt
Terrine Restaurant
Thibiant Beverly Hills
Toscana Restaurant
David Truly
23rd Street Jewelry
UCLA Broad Stem Cell Research
Center
Debbie Valner
Stacy Valner
Velvet by Graham & Spencer
Vince.
Elyse Walker
Wally's Wine and Spirits
Ashley Walton
Claudia Wong
Wood & Vine Restaurant
Edward Woods
Young's Market
Katy Zanville

Our sincere gratitude to those whose generous contributions reached us after press time

WE DO support PHASE ONE

PHASE ONE WALL OF THANKS

Thank you to the nearly 3,000 individuals and businesses that have supported PHASE ONE since our founding. Because of you, we have raised more than \$15 million and funded innovative cancer therapies and clinical trials throughout southern California.

Abber Abbott Abeger Abramhams Abramovitch Abrams Abronson Ackerman
Adam Adams Addington Adelson Adelstein Adrien Aghajani Aglubat Aguado Ahmed
Akerblom Akin Al Alaoui Alanis Alano Alderson Aldisert Alhart Ali Alkon Allard
Allen Allen-Segal Allis Allman Palmer Aloni Alper Alpin Altman Alton Ament Ameri
Amster Andelson Anderson Andes Angarella Angel Angeledes Angepat Anka Ansell
Antenucci Anteyles Antin Apel Appel Applebaum Appleby April Aquino Arana
Araujo Arcy Arena-Nicoll Arenson Argenna Argentieri Argo Arkoff Arlen Arlook
Armand Armetta Armstrong Arnold Aronoff Aronowitz Aronzon Arrillaga Arsuaga
Arutt Ashamalla Ashbee Asher Asherson Assor Aten Atkinson Atlas Attanasio
Atwater James Atwood Auerbach Augunas August Austin Babacoff Babbush Bach
Bachner Bachrach Bader Baer Bahr Baker Balas Baldecchi Baldwin Balkin Ball
Ballarini Bandelt Banducci Banos Barad Baradaran Barber Barcy Baren Barger
Baril Barkhoudarian Barkin Barlava Barnhisel Barrile Barron Barta Basch Bass
Bassman Bastien Bateman Bates Weide Batiste Batra Baum Baumgart Baumgarten
Baxter Beach Beardmore Beattie Beck Beckman Bedil Beebower Beeks Beeman
Behar Beitche Belanger Belfield Bell Beller Belzberg Bender Benedek Benell
Benjamin Benjamin Cohen Bennett Bension Benveniste Benzaken Bercsi Bercu Berg
Berger Bergher Berghoff Bergman Bergsneider Berkett Berkowitz Berkus Berlin
Berman Berman-Masters Bernard Bernardi Bernhard Bernstein Bernt Bertram Best
Bettinsoli Beyda Beyer Bhandari Bider Bieber Biery Bilak Biltz Bindley Binenfeld
Bingham Biren Birnbaum Bitterman Black Blackman Blackmore Blake Blank Blatt
Blatteis Blau Bliese Blitz Bloch Block Blonder Blondman Lax Bloom Bloomfield
Blum Blumenfeld Blumenthal Boesky Bolour Boltor Bomberg Bomes Bond Boone
Boorstin Borden Bordy Boren Borinstein Borman Bornstein Bosse Bosworth Botel
Bottger Botwinick Boucher Bourgeois Bowman Boylan Bradley Brady Braff Brager
Brancato Brander Brandler Brantman Brau Brau Braun Bray Breakstone Bregman
Brende Brendlinger Brener Brenneman Brent Breslauer Bresler Breslin Bresslin
Brewer Bright Brill Briller Brillstein Brindley Brisbin Brisker Briskin Brittan
Brittenham Brock Broder Broffman Broidy Bronson Brookman Brooks Brosnahan
Brotherton Brown Brownstein Bruck Bruckheimer Brufsky Bruggeman Brumer
Bruskoff Brussell Bryan Brylawski Bryson Bub Bubbers Bubser Buc Buch
Buchanan Whipple Buckhantz Buckingham Bucksbaum Burk Burke Burkett Burkle
Burns Bursteen Bushkin Butler Byer Byers Byrd Byron Caan Caffray Cahoon
Callender Calne Cameron Camp Tamakwa Canale Cane Cannava Canny Cano
Cappello Capps Cardoso Carlberg Carlile Carlson Carmack Carmody Carney Carnot
Caron Carrabino Carroll Carter Caruso Case Casemore Casey Cassini Castaneda
Castano Castro Castro-Abeger Cearnal Cedars-Sinai Cerda Chais Chalmers Chalom
Chambers Chamie Champa Chan Chang Chapluk Chasin Chatinsky Cherniak
Chiklis Chin Chiverton Chmara Chmiel Christian Chu Chudd Cicero Cilic City of
Hope Clark Clement Clifford Clippinger Cobb Coden Codikow Cohan Cohen Cohn
Cole Coleman Colin Colleary Collins Colman Combs Conklin Conners-Copeland
Constantiner Content Contreras Cooke Cookler Cooper Coppel Coppersmith Corday
Coren Corman Cornell Corrigan Corso Cort Cortez Corton Corwin Cosgrove
Coskey Costa Cotsen Cottle Counter Cox Coyne Coyne Donnel Craig Cramer

Crandall Crann Crawford Creed Creed Optican Creel Crippen Crofton Cross
Crosson Crown Croxall Crystal Cummins Current Curtis Cuyjet Cycon Daly Damato
Damavandi D'Amour Danelian Daniel Daniels Dano Danpour Danza Dater David
Davidow Davidtz Sloane Davila Davis Dean DeBones de Castro Dedona De Joy De
Kay Del De Leo Delevie Delgado Delone DeLone De Mann Dembo Dempsey Denisi
Dennis De Roy De Santis De Shannon de Shulthess Des Jardins De Turck Deutch
Deutsch Deutschman Dexter Diamond Di Bonaventura Dickerman Dickinson Diemer
Dietz Dietz Lipsett Di Gennaro Dill Diluzio Di Napoli Dinhut Dinkin Di Nome Di Novi
Dinovitz Dishell Dishman Disney Dobkin Dodd Doft Dolgen Doll Domanski
Donahue Doner Dooley Doran Dorfman Doron Doroshov Dorskind Dorst Doumani
Dowell Downing Dresner Dressler Dreyer Dreyfus Driver Drooks Drori Druker
Drumwright Druyanoff Dubbert Dubchansky Dubin Dubrow Duffy Duhl Du Manoir
Dunkle Dunlap Dunleavy Dunn Du Preez Dupuis Duran Dvorak Ebner Eckmann
Edelman Edmiston Edwards Egerman Eghbali Ehrlich Ehrman Eigler Einstein Eisen
Eisenberg Eisenstadt Eisner Ekstrand Elazar Elazer Elfman Elias Elkin Elliot Elman
Emanuel Emerson Emquies Enenstein Engel Engelbrecht Epstein Erlanger
Eshaghian Eshaya Esses Evangelatos Evans Evensen Everman Ezer Ezralow
Factor Fair Falls Family Farber Farrell Farris Feder Feffer Feil Feiler Feinberg
Feld Felder Feldman Feldman Bloom Felice Felix Fellman Felsenthal Feltheimer
Feltz Ferber Feuerman Fickman Fields Fifield Figlin Fine Fineman Fine Marmur
Finerman Fine Tenzer Fini Zanuck Fink Finkelstein Finley Firestein Firestone Firing
Fischer Fish Fishbein Fisher Fishman Fitterman Fitzgerald Fitzpatrick Flagel Flagg
Flahie Flamini Flatow Fleck Fleishman Fleiss Flesh Fletcher Flockhart Fogel
Fogelman Fonda Foos Ford Fordyce Foreman Forester Forman Forrest Forster
Jones Forsyth Foss-Brown Foster Fox Fracchia Fradin Fragen Frandzel Frank
Frankel Frankenheimer Franks Frantz Fraser Freedman Freeman Freitag Fremont
Frenkel Freund Frey Friedberg Friedkin Friedlander Friedman Friedstadt Friend
Friendly Fritz Fryman Fuchs Fuller Fullmer Funk Furie Furlong Bercu Furman Furst
Gaba Gadinsky Gagerman Gale Gallagher Galton Galvan Ganiard Ganz Ganzer
Gaon Gappy Garavente Garbutt Garden Gardner Garfin Garland Garner Garrison
Garvey Gary Gasmer Gaspers Gastaldi Gastelum Gathrid Gaughan Bowman Geffen
Geibelson Gelb Gelfand Gelfand Stearns Gelfan Stone Gelfond Geller Geller-Fields
Gellman Gendelman Gerard Gerber Gersh Gershwin Gerson Gertz Ghazinouri
Ghoreichi Ghoreishi Ghyzel Gibbons Gifford Gigliotti Gilderman Gilhuly Gillett Gilman
Gilroy Gimbel Gingold Ginsburg Glantz Glaser Glass Glasser Glazer Gleiberman
Glick Glist Glover Gluck Glusker Godessoff Godley Goegan Gold Goldberg
Goldbloom Golden Goldfarb Goldhirsh Goldhirsh-Yellin Goldie Goldman Goldman-
Evans Goldmark Goldrich Goldring Goldsmith Goldstein Goldwyn Gonen Gonor
Gonzalez Good Goodman Goodrich GoodSearch Goodshop Goodson Gordon
Gorelick Goren Gores Gorges Goring Gorleick Gottwald Graboff Grad Graiwer
Grand Grandchamp Grandstaff Grant Gray Green Greenberg Greenblatt Greenburg
Greene Greenlaw Greenlee Greenman Greenspan Greenspun Greenstein Greenstreet
Greenwald Greitzer Grennan Grey Griffin Grigsby Grindon Grob Grosfeld Gross
Grossbard Grossi Grosslight Grossman Grosvenor Gruber Gruman Grushow Guber
Guber Brufsky Guefen Guerin Guidry-Soto Gumpert Gunther Gurney Gussman
Gustavson Gutfreund Gutierrez Gutman Gutstein Gwartz Gwynn Haas Haddad
Hadidi Hahl Hahn Hainna Hall Halper Halpern Halpert Hamer Hamermesh Hamrick
Handelman Hankey Hanning Hans Hansen Harangody Harbert Harding Harewood
Harleston Harold Haroni Harris Harrower Hart Hartman Hartson Hausberg Hausfater
Hayman Hayward Heacock Health Media Heisz Hekmat Held Held Bordy Heller
Heller Gerard Helman Heltzer Hendel Henry Henschel Hensley Hermann Hermelin
Hernandez Herrick Hersh Hershler Hertz Hertzberg Herwick Herz Herzig Herzog
Herzog Millman Hess Hicks Hillman Himy Hindshaw Hinshaw Hirsch Hirschhorn
Hirsh Ho Hoberman Hochman Hochron Hodess Hofflund Hoffman Hoffner

Hofheimer Hogan Holdsworth Holland Hollander Holman Holthouse Holzer Honour
Hopkins Hopper Horky Horowitz Horton Horwich Hoshide Hotchkiss Hou Houck
Howard Huddleston Hudson Hughes Hulce Huling Hunegs Hunt Hurwitz Huvane
Hyat Hyman Ibarra Iglesias Indich Innes Insinger Iovine Isaacs Isaacson Isenberg
Ishak Isley Israel Itkin Iwafuchi Hamer Iwanyk Jackman Jackson Jackson-Zapata
Jacobs Jacobson Jacob Tuvia Jacoby Jaffe Jalali James Jamison Jandaghi Jannol
Jansen Jashni Jaynes Jeffer Jensen Jillings Joel Joelson Johann John Johnson
Johnson Tennant Johnston Joie Jolna Jones Jordan Jossen Julis Kabat Kaeser
Kagan Kahn Kalb Kalin Kalish Kaliski Kallick Kallman Kalt Kaltman Kamark
Kamins Kaner Kanter Kao Kapan Kapinos Kaplan Kapnek Brown Karaahmet
Karathanasis Karen Karmin Karp Karsh Karubian Karz Kashanian Kashefi Kassan
Kasten Katz Kaufman Kay Kaye Kayne Keating Keen Keenan Keighley Keith
Keller Kelley Kelly Kelman Kennedy Kenworthy Kershaw Kessler Ketai Keyes
Keyser Kilgallon Kinsey Kirsh Kirshbaum Kissick Kitaer-Penn Kitt McKinnon Klarman
Kleiman Klein Klein-Kabat Kleinman Klem Kliger Kline Kloves Kluiber Klutznick
Klutznik Knapp Knibb Knight Knoopf Kobylt Kocaya Koch Koenig Kohan Kohl
Kokozos Kolbrenner Komberg Kong Konheim Kono Kopczynski Kopf Kors Kort
Kortschak Korzen Kosove Kostow Kotick Kotler Kouba Koulias Kozberg Kradin
Kraines Kramer Krane Krantz Kranz Krask Krasnow Kraus Kravitz Kreikemeier
Kreisberg Kreitenberg Kremen Kreshek Krevoy Kriegel Kruszenski Krzynowek
Kudrow Kuhny Kumble Kuperman Kurlandsky Kurtz Kurtzman Kushner Kwatinetz
LaBrecque Lachman Lacy Ladenheim Lafferty Laille Laine Lainer Lakin Lambeth
Lampert Landaw Lande Lander Landes Landon Lane Langone Langos Lansing
Lanza Lapin Larbalestier Lasker Lassally Latorre Latt Latter Latt Wiatt Laurie
Lautman Lavinthal Lavoie Lawrence Lawson Lax Layne Lazar Lazaruk Leader
LeBauer Lebow Lebowitz Lechter Leder Lederer Lederer Wells Lederman Lee
Leeds Leevan Leff Lefkowitz Lehrman Leibovitch Leibowitz Leichtman Leigh Leipart
Leiter Lembo Lemelson Lenihan Lentz Leonard LeRay Levant Levenstein Levin
Levine Levine-Blonder Levinson Levisetti Levite Levitt Levy Lewis Lewitt Leyrer
Leyva Lezak Liau Liber Licht Lichtenstein Licker Lieberman Liebling Liguori Limor
Lincenberg Lincoln Lindee Linehan Liner Lipman Lippert Lippman Lipsett Lipshutz
Lipsic Lipsky Buch Lipsztein Lis Listen Litman Littman Litvack Litvak Litwak Litwin
Liu Living Livingston Lloyd Lobel Loewenthal London Longstreet Lonner Loparty
Lopez Lopper Lord Lorenzen Losito Loskota Lotman Louchheim Louie Lourd Lovett
Lowenstein Lowry Lowy Lu Lubens Lublin Lucas Luchs Lukoff Luna Lundy Lurie
Lurie Spetner Luskin Lustig Luxenberg Lynch Lyon Lyons Mack Mackey MacRae
Mahl Mahmood Mahmoodzadegan Maiman Mallory Maloney Mancino Mandel
Mandelbaum Mann Mansaury Manze Mapes Marantz Marchetti Marciano Marcil
Marcus Marek Margolis Mariano Marin Marinova Markman Markowitz Marks Marmur
Maron Marquinez Marsh Marshall Martin Martin DeLuca Martinez Masin Mason
Massman Masters Masuda Mathes Mathews Matloff Matsuhisa Matus Matz
Mavredakis Maxima Maxwell Maybank Mayer Mayfield Junior School Mayman Mazirow
Mazur Mazursky McCabe McCain-Tharnstrom McCartney McCorduck McCoy
McCubbin McDonald McDonnell McEvoy McGinley McGovern McGrath McMillan
McMorrow McMullin McNamara McNitt McPhearson McPherson McStay Meadow
Meadow Phillips Meehan Mehrens Mehta Melamed Meleo-Bernstein Mellon Melman
Melmed Meltzer Menard Mendelsohn Mendelson Mercer Merin Merrill Merriman
Messick Messing Messinger Metropolis Retail Inc. Metzinger Meyer MGL Michelman
and Robinson Michelson Milken Milken Bernstein Millard Miller Millman Mills Milstein
Minas Mindel Mindlin Minerd Mintzer Mintz Gathrid Mirkin Miskei Missaghieh Mitchell
Mitteldorf Mizel Mobasser Moelis Moffitt Mogel Mogy Mohr Moir Moiseeff Mayman
Monestere Monkarsh Monroe Montalba Montgomery Montminy Montrone Moore
Moran Moray Moreno Greenlee Morgan Morgerman Morguelan Moriarty Moritz Morris
Morrish Morrison Morrissey Morse Lebow Mortell Morton Mosbat Moss Moursi

Mozur Mueller Muldoon Mullen Mulvehill Munoz Murawa Murphy Murray Myers
Myerson Myman Nachtomi Nadel Nadrich Naegele Naficy Naft Naftali Naftzger
Nakaoka Nanji Nathan Nathan Family Foundation Nathanson Natterson Navarre
Nazarian Nederlander Neiman Nellor Nelson Neman Nemeroff Nesbitt Neufeld
Neumann Newberg Newfield Newlander Newman Newton Howard Ngo Nichol Nickoll
Nicolayevsky Nicole Nicoletti Nicoll Nii Nix Nordstrom Norris Nossel Novick Nunan
Nyman Oakes Slavich O'Brien O'Connor Offer Offsay Ohlmeyer Oillataguerre Oks
Okum Olan Olofson Olshansky Olson O'Malley O'Mara O'Neil Onen Oppenheim
Optican Orser Osterhout Ostin Ostroff Ostrow Oswaks Otte Overholser Owen
Owens Paasche Pack Paget Paik Painter Pakula Palermo Palinkov Palmer
Papalian Parker Parks Parnell Parsa Parvaresh Parzen Passman Pattison Paul
Paulsen Pauly Paura Paykos Payne Peacock Pearlman Pearson Pecaut Peecook
Peele Pelayo Peloso Peltz Penner Penske Pepp Perenchio Perison Perkins
Perlman Permut Pernice Perry Peters Petersen Peterson Petschek Pfeffer Phelps
Phillips Phu Pian Piantadosi Piccioni Piccirillo Pickel Barger Piehl Pierson Pina
Pinchus Pinkner Piro Pistor Pitt Platt Platz Plonsker Plunkett Plutsky Po Pogue
Polak Policella Polidoro Polinsky Pollack Pollack Fox Polson Polster Polster Hankey
Pomerance Pomerantz Pomeroy Pompan Pooya Popofsky Kramer Porter Posnick
Post Poster Powell Poyer Prather Praw Present Pretlow Price Prins Pritzker
Prober-Cohen Prost Prudente Prunier Pulier Pullman Puopolo Purcelli Puri Quaranta
Quigley Quint Rabbani Rabineau Rabow Racujee Rader Radow Radzik Radziner
Rago Raich Raiher Raimi Raissen Raker Ramberg Ramser Ramsey Rams Football
Ranan Randall Randolph Rankin Ransohoff Rapaport Rappaport Rasansky Russell
Ratner Rautbort Ravich Ravich McNitt Rawjee Ray Redlin Reece Reed Regas
Reid Reilly Reims Reinfeld Reisman Reiter Resch Resnick Resnikoff Ressler
Reubel Revitz Reznick Rhee Hindshaw Rhein Rhode Rhodes Rice Riceberg Rich
Richards Richards Sachs Richbook Richker Richman Richter Riddell Riepe Riera
Rierson Rifkin Riggs Riley Risiko Ritter Simon Rivera Robbins Roberts Roberts
Freeman Robinson Robles Robson Rocchio Rockwell Rodan Rodgers Rodriguez
Rogers Rohde Roll Giving Romano Romick Romm Roos Rose Rosedale Rose
Foundation Rosen Rosenbaum Rosenberg Rosenblood Rosenbloom Rosenblum
Rosenfeld Rosenfield Rosenthal Ross Rossen Rosti Rotell Rotenberg Roth
Rothenberg Rothfeld Rothman Rotner Rousselot Roveda Rowen Royce Rozelle
Rubaum Rubin Ruderman Rudnai Rudnick Rush Rusk Russakoff Russel Ford
Russell Russo Ruxin Ryan Ryback Rylance Sabah Sabel Sachs Sachse Sack
Sacks Saevitzon Saferstein Saha Sahlein Saidinia Sain Sakalis Salathe Saliman
Salka Sall Salo Salzman Samek Samuel Sanchez Sanchez-Lazer Sanchini
Sandekian Sanders Sandler Sands Sanger Sanitsky Santos Saperstein Sarkisian
Sarnoff-Ross Saslow Sassaman Sassi Satchu Saunders Schaer Schaffer Scharkss
Schechter Scheck Scheckter Scheetz Schenkel Schenkman Scher Schettig Schiff
Schinderman Schlessel Schlessinger Schneider Schneiderman Schnider Schoelen
Schotz Schrage Schrage Schreiber Schubach Schwartz Schweitzer Schwimmer
Scott Seabold Seacrest Second Street Seeburger Segal Segel Segor Seitz Selby
Sellers Semel Serber Sertner Serviss Sexton Shabani Shadyac Shafer Shagrin
Shams Shanfeld Shanus Shapiro Sharifi Sharpe Shearmur Sheets Sheinberg
Sheinfeld Sher Sheresky Sherman Sherwood Sheth Shilling Shine Shirinyaw Shlafer
Shoenfeld Shokrian Sholem Shore Shpelfogel Shpiner Shriver Shrum Shulman
Shuman Shuster Siciliao Siebert Siegel Siegler Siegler Rothberg Sieveking Sigal
Sigoloff Silber Silberkleit Silberling Silberman Silberstein Silbert Silfen Silverman
Silvers Silverstein Silverton Simchowitz Simon Simonds Simone Simonian Simons
Sims Wood Sind Sindell Singer Singh Sirulnick Sischo Sisino Sisteron Sixx Skerik
Skoro Skvarla Skylar Slater Slatkin Slavich Sloane Slobin Slocum Slomowitz Small
Smidt Smilen Smith Smolberg Smolin Smolinisky Smooke Snider Snyder Soares
Sobel Sofro Sohayegh Baradarian Soh Woods Sokol Sokoloff Solnit Solomon Solov

Solton Somer Somers Sones Soni-Mehta Soofer Sorkin Soros Sorotzkin Soto
Spaeth Spalding Spector Spectrum Spetner Spezio Spiegel Spilka Spink Spinner
Spiro Spitz Sponco Spound Sprung Spungin Spyksma Sraberg Sri-Kumar Staggs
Stahman Stamen Arrillaga Stanley Stark Starkman Stearn Stearns Stein Steinberg
Steiner Steinfeld Stelzer Sterling Stern Stevens Stewart Stoff Stokdyk Stolaroff
Stone Stowell Ford Straberg Strasmore Strauss Strempek Strickler Studebaker Stupp
Styne Suddleson Sudikoff Sue Sugar Sugarman Sugerman Sukkert Sunkin Suskin
Susskind Sussman Sutton Swalwell Swan Swanky Swanson Swardstrom Swartz
Swedlin Sweeney Swiller Swindells Sykes Tabach-Bank Takowsky Tanenbaum
Tannenbaum Tapper Tarin Tarnofsky-Ostroff Tarses Tashman Tate Tavangarian
Tavares Taylor Tebbe Meyer Tehrani Teiger Temkin Tenebaum Tennant Tenner
Tenzer Tessler Tharnstrom Theony Thom Thomas Thomopoulos Thompkin-Dobkin
Thompson Thorne Thorson Thurnher Tidyman Tiger Tilchin Tile with Style Tilkian
Tippl Tipton Tisch Titan Tobey Todd Tolkin Tollman Tolot Tolson Toplitzky Toppel
Towner Townsend Tractenberg Tracy Tranen Trachtenberg Trattner Treadwell Trepp
Trehitt Trostler Tsabag Tucker Tuckman Tuli Turkell Turnbull Turner Turteltaub
Tuvia Twilley Uchikura Ullman Umansky Unger Upchurch Uslaner Uzielli Vahn
Vaiman Valentine Valner Van de Bunt Van Donge Vaneckert Van Gilder Vann Varney
Velkes Vella Venit Venturelli Verdadero Vertoch Vetter Victor Vidergauz Vimeo
Vincent Viola Volpert Von Wooster Vorhoff Vradenburg Wachtel Waddler Wadler
Wagman Wagmeister Wagner Wahlstrom Walden Waldstein Walentas Walker
Wallace Wallach Wallach Kleinman Walston Wander Wang Ward Wardle Warren
Wasser Wasserman Waxman Wearstler Webb Webber Weber Webster Wechsler
Wecker Weed Weetman Weg Weide Weidenfeller Weil Weiman Weinberg
Weinberger Weiner Weingarten Weinstein Weinstock Weintraub Weisbarth Weisberg
Weisenberg Weiser Weisman Weiss Weissberg Weisskopf Weissman Weitman Weitz
Weitzman Welch Wells Welsh-Hanning Wenokur Wertheimer Wexler Whalen
Wheeler Whipple Whitebook Whitesell Whitman Whittaker Wick Wiczky Wilchfort
Wild Wilf William Williams Wilson Wilstein Wimer Winebaum Winkler Winnick
Winsberg Winston Winter Winters Winton Wintrob Witenberg Witham Witherspoon
Witmer Witten Wolcott Wolens Wolf Wolfen Wolff Wolf Klein Wolk Wolken Wong
Woo Wood Woodruff Woods Woodward Woolfe Worchell Woronoff Wozniak Wright
Wrigley Wrublin Wyman Wynn Yaffe Yagan Yamarone Yanow Yaw Yazedjian
Yellin Yip Youd Young Younger Yuhashi Yung Zafran Zaga Zaharia Zahn Zajfen
Zalaznick Zanuck Zanville Zapata Zara-Kobylt Zarnegin Zeegen Zeiden Ziering
Ziffren Zifkin Zilber Zimbert Zimmer Zimmerman Zinberg Zinman Kohl Zisls Zisman
Zohar Zoller Zommick Zubery Zuckerman Zukor Zundeleovich Zuriff Zwahlen Zweben
Zwick Zwilling

WE DO support PHASE ONE

STAYING IN TOUCH

*Learn more about PHASE ONE, including our latest grants,
upcoming events and news about cancer research.*



FACEBOOK • INSTAGRAM • TWITTER
@PhaseOneLA



256 - 26th Street, Suite 201
Santa Monica, CA 90402
310-458-7715 phone
310-393-6051 or 818-505-9170 fax
www.phaseonefoundation.org
info@phaseonefoundation.org

WE DO support PHASE ONE

***Thank you for being
part of our 15th Gala &
our Virtual Journal***

• • •

***You DID support
PHASE ONE***